Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Atezolizumab (Tecentriq) for Non-Small Cell Lung Cancer 
(Final Recommendation Issued as of June 20, 2018)

Lenvatinib (Lenvima) for Advanced Renal Cell Carcinoma
(Open for Input on Submission until June 22, 2018)

Blinatumomab (Blincyto) for Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia
(Pending Submission as of May 31, 2018)

Belinostat (Beleodaq) for Peripheral T-Cell Lymphoma
(Pending Submission as of May 31, 2018)

Lutetium Lu 177 dotatate (Lutathera) for Gastroenteropancreatic Neuroendocrine Tumors
(Pending Submission as of May 9, 2018)

 

 

Find a Drug Review